In 2005 The Global Antibacterial Market Was Valued At Approximately $25.5 Billion

Business Wire, April 5, 2007

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c53518) has announced the addition of "Commercial Insight: Antibacterials - Growth in Resistance Rates Drives Niche Indications" to their offering

The global antibacterial market, valued at $25.5 billion in 2005, is highly mature. Modest growth (CAGR 2001-2005: 5.1%) is fuelled by ageing, immunosuppression and emerging resistances, especially in the hospital and former niche markets (e.g. MRSA). The community market, however, is facing a value loss following the patent expiries of several blockbusters (e.g. Pfizers Zithromax) in 2005.

Scope of this title:

* In-depth analysis of the current antibacterial market situation across the 7 major markets (US, Japan, France, Germany, Italy, Spain, UK)

* Thorough assessment of underlying commercial and clinical influencers shaping the antibacterial market

* Detailed sales forecasts for key antibacterial classes, molecules and brands in each of the seven major markets

* Case study analysis of lifecycle management strategies for Zithromax (Pfizer), Rocephin (Roche) and Biaxin (Abbott) and assessment of their success

Highlights of this title:

* In 2005 the global antibacterial market was valued at approximately $25.5 billion with a modest CAGR of 5.1% since 2001. The fastest growing classes were the carbapenems, glycopeptides and "others" (e.g. Pfizers Zyvox (linezolid)). The best selling drug was J&Js/Sanofi-Aventis Levaquin (levofloxacin) with global sales of $2.4 billion.

* Although gram-positive infections such as MRSA have been a key focus over recent years, our opinion leader research revealed new concerns about gram-negative organisms such as acinetobacter, pseudomonas and ESBL producing strains.

* Ageing, immunosuppression and resistances contribute to the rising incidence of severe infections and fuel the growth of the hospital market. In contrast, the community market is facing a value loss resulting from the patent expiries of blockbusters such as Zithromax (azithromycin) and the incursion of cheap generics.

Reasons to order your copy:

* Review the clinical and commercial factors driving new product decisions in antibacterials, and the opportunities and threats facing the market

* Gain insight into future trends and lifecycle management strategies through a detailed market forecast and real case study analyses

* Understand where concerns, unmet needs and future opportunities lie by learning about the views of key antibacterial opinion leaders.

Topics Covered:

* -Market definition and overview

* -Country market assessments

* -Forecast analysis

* -Commercial impact and lifecycle management: case studies

Companies Mentioned:

* -Pfizer

* -Roche

* -Abbott

* -J&Js/Sanofi-Aventis

For more information, visit http://www.researchandmarkets.com/reports/c53518

Source: Datamonitor